Caplin Point inks distribution pact with Fresenius Kabi USA

Caplin Point Laboratories Ltd has signed a license and distribution agreement with Fresenius Kabi USA LLC for parenteral products. Fresenius Kabi is one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
 
“Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialise the same in USA,” said Caplin Point in a BSE filing.
 
This is a product specific agreement for USA, with currently two products featuring in the contract. Caplin Point has already received milestone payments for two products and the product development cum dossier preparation have just commenced.
 
Caplin Point manufacture a wide range of ointments, creams and other external applications in addition to the regular segments of pharmaceutical formulations.